Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313405917> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4313405917 endingPage "66.19" @default.
- W4313405917 startingPage "66.19" @default.
- W4313405917 abstract "Abstract Metastatic triple-negative breast cancer (TNBC) has a poor prognosis primarily due to metastatic potential and resistance to currently available therapies. Recent studies suggest that TNBC may be a viable target for immunotherapy due to the presence of high levels of infiltrating lymphocytes. However, many TNBC patients do not respond due to high intra-tumoral and inter-patient heterogeneity. Utilizing a novel protein transfer method, we generate a personalized vaccine based on tumor membrane vesicles (TMVs) derived from whole tumor tissues modified with glycolipid-anchored forms of the immunostimulatory molecules (GPI-ISMs) B7-1 and IL-12. In prior studies we observed that simultaneous delivery of TMVs along with biological adjuvants enhanced CD8 T cell immunity. Herein, we investigated the impact of standard-of-care (SOC) chemotherapy on the resulting quality of the TMV vaccine. Mice were injected with 4T1 TNBC cells subcutaneously and treated with three rounds of SOC drugs starting at day 15. Chemotherapies affected tumor growth to varying degrees. Mice were euthanized and tumors were harvested for TMV preparation. Results show that depending on the treatment, the yield and particle size of TMVs was impacted. While SOC drugs affected some surface markers on TMVs, expression of CD24 and CD11b was unchanged. Further, there was reduced uptake of TMVs by dendritic cells prepared from cisplatin and 5-fluorouracil treated tumors. GPI-ISMs were equally incorporated by protein transfer onto TMVs despite SOC treatments. In summary, our studies in the 4T1 model show that a TMV vaccine can be successfully prepared after chemotherapy, but the impact on TMV yield and size justifies further investigation. Supported by R01 CA202763" @default.
- W4313405917 created "2023-01-06" @default.
- W4313405917 creator A5013940990 @default.
- W4313405917 creator A5022570672 @default.
- W4313405917 creator A5043413929 @default.
- W4313405917 creator A5057802881 @default.
- W4313405917 creator A5073494284 @default.
- W4313405917 creator A5090887063 @default.
- W4313405917 date "2022-05-01" @default.
- W4313405917 modified "2023-09-25" @default.
- W4313405917 title "Effect of Standard of Care Treatment on Tumor Membrane Vesicle Vaccine for Triple-Negative Breast Cancer" @default.
- W4313405917 doi "https://doi.org/10.4049/jimmunol.208.supp.66.19" @default.
- W4313405917 hasPublicationYear "2022" @default.
- W4313405917 type Work @default.
- W4313405917 citedByCount "0" @default.
- W4313405917 crossrefType "journal-article" @default.
- W4313405917 hasAuthorship W4313405917A5013940990 @default.
- W4313405917 hasAuthorship W4313405917A5022570672 @default.
- W4313405917 hasAuthorship W4313405917A5043413929 @default.
- W4313405917 hasAuthorship W4313405917A5057802881 @default.
- W4313405917 hasAuthorship W4313405917A5073494284 @default.
- W4313405917 hasAuthorship W4313405917A5090887063 @default.
- W4313405917 hasConcept C121608353 @default.
- W4313405917 hasConcept C126322002 @default.
- W4313405917 hasConcept C143998085 @default.
- W4313405917 hasConcept C167672396 @default.
- W4313405917 hasConcept C203014093 @default.
- W4313405917 hasConcept C2776694085 @default.
- W4313405917 hasConcept C2777701055 @default.
- W4313405917 hasConcept C2778239845 @default.
- W4313405917 hasConcept C2780110267 @default.
- W4313405917 hasConcept C502942594 @default.
- W4313405917 hasConcept C530470458 @default.
- W4313405917 hasConcept C71924100 @default.
- W4313405917 hasConcept C8891405 @default.
- W4313405917 hasConceptScore W4313405917C121608353 @default.
- W4313405917 hasConceptScore W4313405917C126322002 @default.
- W4313405917 hasConceptScore W4313405917C143998085 @default.
- W4313405917 hasConceptScore W4313405917C167672396 @default.
- W4313405917 hasConceptScore W4313405917C203014093 @default.
- W4313405917 hasConceptScore W4313405917C2776694085 @default.
- W4313405917 hasConceptScore W4313405917C2777701055 @default.
- W4313405917 hasConceptScore W4313405917C2778239845 @default.
- W4313405917 hasConceptScore W4313405917C2780110267 @default.
- W4313405917 hasConceptScore W4313405917C502942594 @default.
- W4313405917 hasConceptScore W4313405917C530470458 @default.
- W4313405917 hasConceptScore W4313405917C71924100 @default.
- W4313405917 hasConceptScore W4313405917C8891405 @default.
- W4313405917 hasIssue "1_Supplement" @default.
- W4313405917 hasLocation W43134059171 @default.
- W4313405917 hasOpenAccess W4313405917 @default.
- W4313405917 hasPrimaryLocation W43134059171 @default.
- W4313405917 hasRelatedWork W1966181922 @default.
- W4313405917 hasRelatedWork W1999292713 @default.
- W4313405917 hasRelatedWork W2379009234 @default.
- W4313405917 hasRelatedWork W2388730008 @default.
- W4313405917 hasRelatedWork W2534174115 @default.
- W4313405917 hasRelatedWork W2554176272 @default.
- W4313405917 hasRelatedWork W2888577064 @default.
- W4313405917 hasRelatedWork W3000117005 @default.
- W4313405917 hasRelatedWork W363598932 @default.
- W4313405917 hasRelatedWork W80971072 @default.
- W4313405917 hasVolume "208" @default.
- W4313405917 isParatext "false" @default.
- W4313405917 isRetracted "false" @default.
- W4313405917 workType "article" @default.